Published in final edited form as:

Brain Lang. 2013 November ; 127(2): . doi:10.1016/j.bandl.2013.02.004.

Are there susceptibility factors for primary progressive aphasia?

Emily Rogalski¹, Sandra Weintraub^{1,2}, and M.-Marsel Mesulam^{1,3}

¹Cognitive Neurology and Alzheimer's Disease Center, Northwestern University (NU) Feinberg School of Medicine, Chicago, IL, USA

²NU Feinberg School of Medicine, Department of Psychiatry and Behavioral Sciences, Chicago, IL, USA

³NU Feinberg School of Medicine, Department of Neurology

Abstract

The determinants of selective vulnerability in neurodegenerative diseases remain elusive. The asymmetric loss of neurons in primary progressive aphasia offers a unique setting for addressing this question. Although no factor can yet account for the selective vulnerability of the left hemisphere language network to degenerative diseases, a few themes are emerging as potential targets of further investigation.

Keywords

Risk factors; dementia; learning disabilities; APOE; dyslexia; vasectomy

1. Introduction

Neurodegenerative diseases can be classified by the molecular nature of the proteinopathy, the cellular aspects of the pathology, the anatomical distribution of the neurosynaptic loss, or the clinical features of the resultant phenotype. No neurodegenerative disease is truly global, especially at the initial stages during which selective anatomical distributions determine distinctive clinical phenotypes. In the case of dementias, major subtypes such as those with predominantly *amnestic*, *visuospatial*, *comportmental* and *aphasic* impairments reflect the initially preferential involvement of mediotemporal, parietooccipital, prefrontal and temporosylvian cortices, respectively (S Weintraub & Mesulam, 1993). The amnestic phenotype is also known as the dementia of the Alzheimer-type (DAT), the visuospatial phenotype as posterior cortical atrophy (PCA), the comportmental phenotype as behavioral variant frontotemporal dementia (bvFTD), and the aphasic phenotype as primary progressive aphasia (PPA).

In contrast to the consistent relationship between anatomy and clinical features, the relationship of the clinical picture to the underlying disease process in neurodegenerative dementia is anything but consistent. For example, the PPA phenotype can be caused by the

© 2013 Elsevier Inc. All rights reserved

Corresponding Author: Emily J Rogalski Northwestern University Cognitive Neurology and Alzheimer's Disease Center (CNADC) 320 E Superior Street Searle Building 11th Floor Chicago, IL 60611 312-503-1155 phone 312-908-8789 fax erogalski@gmail.com.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

neuropathology of either Alzheimer's disease (AD) or of frontotemporal lobar degeneration (FTLD). The FTLD in these patients can arise either sporadically or in conjunction with mutations that lead to dominantly inherited disease. Furthermore, identical mutations in dominantly inherited FTLD can cause different clinical patterns of impairment within the same family (Bird et al., 1999; M. Mesulam et al., 2007; Rademakers et al., 2007; Simon-Sanchez et al., 2012; Snowden et al., 2006). Similarly, Alzheimer pathology, known to display a predominantly limbic distribution of initial neurodegenerative change and a corresponding amnesic phenotype in the vast majority of cases, can have atypical distributions that occasionally lead to behavioral, visuospatial, or aphasic phenotypes, including PPA (Gefen et al., 2012; M. Mesulam et al., 2008). The phenotype in neurodegenerative disease therefore seems to reflect complex interactions between molecular factors that underlie neurosynaptic death, on one hand, and individual susceptibility factors that determine the anatomy of degeneration, on the other. The goal of this review is to introduce a few themes that may eventually become pertinent to the identification of factors underlying the selective susceptibility of the language network to neurodegeneration in PPA.

2. Search for Genetic Factors

2.1 Potential Clues in *GRN* Families

The majority of PPA cases associated with FTLD neuropathology are sporadic. However, PPA has also been reported in dominantly inherited forms of FTLD with mutations in *MAPT*, *GRN* or *C9orf72* (Cooper-Knock et al., 2012; Munoz, Ros, Fatas, Bermejo, & de Yebenes, 2007; Pickering-Brown et al., 2008; Simon-Sanchez et al., 2012). In the group of dominantly inherited dementias, the PPA phenotype has been described most frequently in families with a point mutation on chromosome 17 in the *GRN* gene that encodes progranulin and leads to a haploinsufficiency syndrome. In these families, some of the affected individuals may display the PPA phenotype while others display the bvFTD phenotype (Rademakers et al., 2007). There are, however, some exceptions. In two families, *GRN* mutations resulted in the PPA phenotype in all affected members (M. M. Mesulam et al., 2007). In the PPA1 family, three of four siblings had PPA. The mutation consisted of a single nucleotide deletion in exon 9. In the PPA3 family, two of three siblings had PPA. The mutation was a C>T transition in exon 11. Both mutations resulted in a premature termination codon and a haploinsufficiency of progranulin. Affected members of both families showed FTLD-TDP Type A pathology, where inclusions containing the transactive response DNA-binding protein 43 (TDP-43) were asymmetrically distributed with a greater concentration in the left hemisphere language cortices (Gliebus et al., 2010). Families with this type of homogeneous PPA phenotype hold considerable promise for exploring factors that make the left hemisphere language network selectively susceptible to progranulin deficiency.

2.2 ApoE

As mentioned above, the PPA phenotype can emerge in association with the amyloid plaques and neurofibrillary tangles (NFT) of AD (M. M. Mesulam & Weintraub, 1992). However, in such cases, the NFTs have an atypical and clinically concordant distribution that is quite different from what is seen in DAT. Specifically, the NFTs in PPA display higher left-to-right and neocortical-to-entorhinal ratios than in patients with the DAT phenotype (Gefen et al., 2012). One question is whether the differential distribution of neurofibrillary degeneration in AD might be associated with differences of genetic background. This question was addressed in a study that looked at the prevalence of molecular forms of the Apolipoprotein E gene (*ApoE*). The $\epsilon 4$ allele of *ApoE* is a known genetic risk factor for typical AD, namely an age-related neurodegeneration associated with

the amnesic DAT phenotype. In our autopsy series of patients *with proven Alzheimer pathology*, we found that the frequency of the e4 allele was no higher in patients with the PPA phenotype than in the controls, whereas, as expected, the frequency of this allele was significantly higher in patients had the typical amnesic DAT phenotype (Gefen et al., 2012). It appears, therefore, that e4 is not a general risk factor for *all* Alzheimer pathology, but *specifically* for the Alzheimer pathology that leads to the amnesic DAT phenotype and preferential atrophy of mediotemporal limbic cortices (Rogalski et al., 2011). Circumstantial support for this speculation comes from an experiment showing that neurologically intact subjects carrying at least one $\epsilon 4$ allele displayed reduced hippocampal volume, as if the $\epsilon 4$ allele might exert a developmental influence that makes medial temporolimbic structures more susceptible to involution and perhaps also to neurofibrillary pathology (Lind et al., 2006). Further exploration of how the $\epsilon 4$ allele of *ApoE* differentially influences the vulnerability of mediotemporal versus left perisylvian cortex to neurodegeneration may indirectly help to identify susceptibility factors for PPA.

2.3 Prion Protein

One of the most interesting genetic clues related to selective vulnerability comes from the field of prion proteins. Two of the best-known phenotypes of genetic prionopathies are Creutzfeldt-Jacob disease, which causes predominantly cortical degeneration, and Fatal Familial Insomnia, which causes predominantly thalamic degeneration. Although the mutation of the prion protein gene (*PRNP*) is on codon 178 for both phenotypes, the nature of the polymorphism on codon 129 of *PRNP* influences whether the pathology is cortical or thalamic. One question is whether codon 129 polymorphisms also influence disease distribution in other degenerations.

In an initial investigation, we found that the methionine/valine (MV) polymorphism of codon 129 was overrepresented in PPA compared to controls, bvFTD, and motor neuron disease (Li et al., 2005). This preliminary finding raised the possibility that polymorphisms of codon 129 could influence the selective susceptibility of the language network to neurodegeneration even when the disease is not related to a prionopathy. However, two other studies (Premi et al., 2012; Rohrer et al., 2006), have failed to replicate our results. In the future, it may be useful to repeat this investigation in a larger group of PPA cases with known neuropathology.

2.4 FOXP2

Mutations of the forkhead box P2 gene (*FOXP2*) in the KE kindred has been linked to relatively specific speech and language impairments (Fisher, Vargha-Khadem, Watkins, Monaco, & Pembrey, 1998; Lai, Fisher, Hurst, Vargha-Khadem, & Monaco, 2001). This relationship has stimulated a great deal of interest in trying to identify whether *FOXP2* polymorphisms influence the susceptibility to PPA. In one study on patients with clinically diagnosed FTL spectrum syndromes, the rs1456031 and rs17137124 polymorphisms were associated with hypoperfusion in the left inferior frontal gyrus and lower verbal fluency (Padovani et al., 2010). However, these *FOXP2* polymorphisms did not differentiate PPA from controls (Premi et al., 2012). Of even greater interest is the finding that a polymorphism of *KIAA0319/TTRAP/THEM2*, a gene that is thought to be associated with dyslexia, influences the laterality of activation in the superior temporal sulcus (Pinel et al., 2012). In some way or another, these two genes seem to asymmetrically influence the activity of the two hemispheres, specifically within areas related to language function. Further work on these genes and their potential interactions with *GRN*, *ApoE* and *PRNP* remain promising avenues for exploring the putative molecular basis of selective vulnerability in PPA.

3. Search for Developmental and Acquired Factors

3.1 Learning disability

A study in a group of 699 subjects found that a history of learning disability, including developmental dyslexia, is significantly higher in PPA patients and their first-degree relatives than either in controls or in patients with the DAT or bvFTD phenotypes (Figure 1). In several of the PPA families there were unusually high concentrations of specific reading and spelling difficulties. For example, one of the PPA probands in this study reported that he did not learn to read until the age of 9–10 and that his spelling has always been poor. All three of his children and both granddaughters were reported as dyslexic. It is worth noting that the patient as well as all three sons managed to build successful careers emphasizing computers and sports. Another proband, who denied a personal history of learning disability, reported that all five of his siblings had difficulties with learning to read or spell. One of the PPA patients reported that his father was a stutterer. Dyslexia is known to run in families and has been associated with numerous genetic susceptibility loci (Cardon et al., 1994; Tzenova, Kaplan, Petryshen, & Field, 2004). If a sufficiently large PPA sample can be gathered, it may be possible, to explore if any of these genes are also risk factors for PPA. In some cases such susceptibility genes may interfere with the initial development of language and lead to developmental dyslexia, in others the effect may remain compensated for decades but resurface as PPA through a selective vulnerability of the language cortex to neurodegeneration.

3.2 Focal structural lesions

The apparently higher frequency of learning disability in individuals with PPA and first degree relatives has led to the hypothesis that PPA may represent a late manifestation of a developmental or genetic weakness of the language network that becomes functionally compensated during most of adulthood but which then offers a locus of maximal vulnerability to degenerative diseases. Circumstantial support for this concept of anatomically targeted susceptibility comes from three individuals in whom early damage to the left cerebral hemisphere remained silent with respect to language function until the seventh decade of life at which time it became associated with the emergence of typical PPA. Two of the patients had left hemicraniosynostosis, a congenital condition that caused the premature closure of cranial sutures on the left side of the skull and decreased volume of the underlying left frontal and temporal lobes (Alberca, Montes, Russell, Gil-Neciga, & Mesulam, 2004). The third patient had a history of an abscess that had been surgically removed from the left temporal lobe at age 11 (M. M. Mesulam & Weintraub, 1992). These three cases are mentioned to support the 'locus of least resistance' concept, not to imply that prior injury is a general risk factor for PPA.

3.3 Vasectomy

There would have been no reason whatsoever to look at the incidence of vasectomy in PPA had it not been for one of our patients who urged us to look into this possibility because he was convinced that his PPA had been caused by a vasectomy. This prompted an initial investigation, which found that 40% of 47 patients with PPA had a vasectomy while only 16% of 57 cognitively healthy individuals had the procedure, a difference that was statistically significant (Figure 2a). An unpublished replication study on a new sample of 194 subjects showed that the vasectomy prevalence was 9.7% in 93 men with normal cognition, 18.2% in a group of 44 men with bvFTD, and 38.6% in 57 men with PPA (Figure 2b). The comparison between the cognitively healthy group and the PPA group was statistically significant when adjusted for age, education, or both ($p < 0.0001$). The vasectomy rate in the bvFTD group was not significantly different statistically from controls but did differ from the PPA group ($p < 0.02$ when adjusted for education or age).

A relationship of PPA to vasectomy may initially appear quite implausible. However, there are a few points that may deserve further attention. For example, approximately two thirds of men who have a vasectomy are known to form antibodies to sperm that can persist for many years (Ansbacher, 1973, 1981; Heidenreich, Bonfig, Wilbert, Strohmaier, & Engelmann, 1994; Linnet, 1983, 1993). Cross-reactivity between brain and sperm has been reported, including the shared presence of 3 neural surface antigens (NS-4, NS-6, and NS-7) (Chaffee & Schachner, 1978a, 1978b; Schachner, Wortham, Carter, & Chaffee, 1975). The cytoskeletal protein tau has been found only to exist outside of the CNS in the manchette of sperm (Ashman, Hall, Eveleth, & Boekelheide, 1992). We therefore speculated that vasectomy may trigger an autoimmune process, akin to paraneoplastic encephalitis, which somehow interacts with the primary neurodegenerative disease to make the language network the major site of neurosynaptic loss (S. Weintraub et al., 2006). Such autoimmune processes can have a great deal of anatomical specificity for different neuronal populations, and pronounced hemispheric asymmetry as in the case of Rasmussen's encephalopathy (Bien et al., 2005). There is currently no evidence of an overt immune-mediated neuropathology in PPA so that this suggested mechanism must remain highly speculative.

4. Conclusions

The PPA syndrome can be caused by numerous species of neurodegeneration, each of which can also lead to phenotypes other than PPA. Although the cellular nature of the underlying neurodegeneration is heterogeneous, all PPA shares the common denominator of asymmetrical atrophy in the language-dominant (usually left) hemisphere. The fact that identical neuropathological entities can cause PPA in some patients while causing bvFTD or amnesic dementias in others justifies the search for susceptibility factors that interact with the neurodegenerative disease to determine its primary anatomical location. No such susceptibility factor has yet been identified in any of the dementia syndromes and the one in PPA remains as elusive as ever. The strongest lead thus far is the high incidence of learning disabilities. This relationship will need to be confirmed and pursued with appropriate investigation of relevant genetic markers. Eventually, the identification of susceptibility factors in PPA stands to have far-reaching implications for understanding the mechanisms of selective vulnerability and also for elucidating the distinctive biological fingerprints of the language network.

Acknowledgments

This work was supported by the following Grants: DC008552 from the National Institute on Deafness and Communication Disorders (NIDCD), AG13854 (the Alzheimer Disease Center) from the National Institute on Aging (NIA), NS075075 from the National Institute of Neurological Disorders and Stroke (NINDS), and 5KL2RR025740 from the National Center for Research Resources. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.

References

- Alberca R, Montes E, Russell E, Gil-Neciga E, Mesulam M. Left hemispheric hypoplasia in 2 patients with primary progressive aphasia. *Arch Neurol*. 2004; 61(2):265–268. [PubMed: 14967776]
- Ansbacher R. Vasectomy: sperm antibodies. *Fertility and Sterility*. 1973; 24(10):788–792. [PubMed: 4741999]
- Ansbacher R. Humoral sperm antibodies: a 10-year follow-up of vas-ligated men. *Fertility and Sterility*. 1981; 36(2):222–224. [PubMed: 7262338]
- Ashman JB, Hall ES, Eveleth J, Boekelheide K. Tau, the neuronal heat-stable microtubule-associated protein, is also present in the cross-linked microtubule network of the testicular spermatid manchette. *Biology of Reproduction*. 1992; 46(1):120–129. [PubMed: 1547309]

- Bien CG, Granata T, Antozzi C, Cross JH, Dulac O, Kurthen M, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. *Brain : a journal of neurology*. 2005; 128(Pt 3):454–471. [PubMed: 15689357]
- Bird TD, Nochlin D, Poorkaj P, Cherrier M, Kaye J, Payami H, et al. A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L). *Brain*. 1999; 122(Pt 4):741–756. [PubMed: 10219785]
- Cardon LR, Smith SD, Fulker DW, Kimberling WJ, Pennington BF, DeFries JC. Quantitative trait locus for reading disability on chromosome 6. *Science*. 1994; 266(5183):276–279. [PubMed: 7939663]
- Chaffee JK, Schachner M. NS-6 (nervous system antigen-6): a new cell surface antigen of brain, kidney, and spermatozoa. *Developmental Biology*. 1978a; 62(1):173–184. [PubMed: 340308]
- Chaffee JK, Schachner M. NS-7 (nervous system antigen-7): a cell surface antigen of mature brain, kidney, and spermatozoa shared by embryonal tissues and transformed cells. *Developmental Biology*. 1978b; 62(1):185–192. [PubMed: 563819]
- Cooper-Knock J, Hewitt C, Highley JR, Brockington A, Milano A, Man S, et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. *Brain : a journal of neurology*. 2012; 135(Pt 3):751–764. [PubMed: 22366792]
- Fisher SE, Vargha-Khadem F, Watkins KE, Monaco AP, Pembrey ME. Localisation of a gene implicated in a severe speech and language disorder. *Nature Genetics*. 1998; 18(2):168–170. [PubMed: 9462748]
- Gefen T, Gasho K, Rademaker A, Lalehzari M, Weintraub S, Rogalski E, et al. Clinically concordant variations of Alzheimer pathology in aphasic versus amnesic dementia. *Brain : a journal of neurology*. 2012; 135(Pt 5):1554–1565. [PubMed: 22522938]
- Gliebus G, Bigio EH, Gasho K, Mishra M, Caplan D, Mesulam MM, et al. Asymmetric TDP-43 distribution in primary progressive aphasia with progranulin mutation. *Neurology*. 2010; 74(20):1607–1610. [PubMed: 20479359]
- Heidenreich A, Bonfig R, Wilbert DM, Strohmaier WL, Engelmann UH. Risk factors for antisperm antibodies in infertile men. *American Journal of Reproductive Immunology*. 1994; 31(2–3):69–76. [PubMed: 8049027]
- Lai CS, Fisher SE, Hurst JA, Vargha-Khadem F, Monaco AP. A forkhead-domain gene is mutated in a severe speech and language disorder. *Nature*. 2001; 413(6855):519–523. [PubMed: 11586359]
- Li X, Rowland LP, Mitumoto H, Przedborski S, Bird TD, Schellenberg GD, et al. Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia. *Ann Neurol*. 2005; 58(6):858–864. [PubMed: 16315279]
- Lind J, Larsson A, Persson J, Ingvar M, Nilsson LG, Backman L, et al. Reduced hippocampal volume in non-demented carriers of the apolipoprotein E epsilon4: relation to chronological age and recognition memory. *Neuroscience Letters*. 2006; 396(1):23–27. [PubMed: 16406347]
- Linnet L. Clinical immunology of vasectomy and vasovasostomy. *Urology*. 1983; 22(2):101–114. [PubMed: 6349086]
- Linnet L. Vasectomy and health revisited. *International Journal of Andrology*. 1993; 16(3):169–173. [PubMed: 8359930]
- Mesulam M, Johnson N, Krefft TA, Gass JM, Cannon AD, Adamson JL, et al. Progranulin mutations in primary progressive aphasia: the PPA1 and PPA3 families. *Archives of Neurology*. 2007; 64(1):43–47. [PubMed: 17210807]
- Mesulam M, Wicklund A, Johnson N, Rogalski E, Leger GC, Rademaker A, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. *Ann Neurol*. 2008; 63(6):709–719. [PubMed: 18412267]
- Mesulam MM, Johnson N, Krefft TA, Gass JM, Cannon AD, Adamson JL, et al. Progranulin mutations in primary progressive aphasia: the PPA1 and PPA3 families. *Arch Neurol*. 2007; 64(1):43–47. [PubMed: 17210807]
- Mesulam MM, Weintraub S. Spectrum of primary progressive aphasia. *Bailliere's clinical neurology*. 1992; 1(3):583–609.

- Munoz DG, Ros R, Fatas M, Bermejo F, de Yebenes JG. Progressive nonfluent aphasia associated with a new mutation V363I in tau gene. *Am J Alzheimers Dis Other Dement*. 2007; 22(4):294–299. [PubMed: 17712160]
- Padovani A, Cosseddu M, Premi E, Archetti S, Papetti A, Agosti C, et al. The speech and language FOXP2 gene modulates the phenotype of frontotemporal lobar degeneration. *Journal of Alzheimer's disease : JAD*. 2010; 22(3):923–931.
- Pickering-Brown SM, Rollinson S, Du Plessis D, Morrison KE, Varma A, Richardson AM, et al. Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. *Brain : a journal of neurology*. 2008; 131(Pt 3):721–731. [PubMed: 18192287]
- Pinel P, Fauchereau F, Moreno A, Barbot A, Lathrop M, Zelenika D, et al. Genetic variants of FOXP2 and KIAA0319/TTRAP/THEM2 locus are associated with altered brain activation in distinct language-related regions. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2012; 32(3):817–825. [PubMed: 22262880]
- Premi E, Pilotto A, Alberici A, Papetti A, Archetti S, Seripa D, et al. FOXP2, APOE, and PRNP: New Modulators in Primary Progressive Aphasia. *Journal of Alzheimer's disease : JAD*. 2012; 28(4): 941–950.
- Rademakers R, Baker M, Gass J, Adamson J, Huey ED, Momeni P, et al. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. *Lancet neurology*. 2007; 6(10):857–868. [PubMed: 17826340]
- Rogalski EJ, Rademaker A, Harrison TM, Helenowski I, Johnson N, Bigio E, et al. ApoE E4 is a Susceptibility Factor in Amnesic But Not Aphasic Dementias. *Alzheimer disease and associated disorders*. 2011; 25(2):159–163. [PubMed: 21346518]
- Rohrer JD, Mead S, Omar R, Poulter M, Warren JD, Collinge J, et al. Prion protein (PRNP) genotypes in frontotemporal lobar degeneration syndromes. *Ann Neurol*. 2006; 60(5):616. author reply 617. [PubMed: 16969862]
- Schachner M, Wortham KA, Carter LD, Chaffee JK. NS-4 (nervous system antigen-4), a cell surface antigen of developing and adult mouse brain and sperm. *Developmental Biology*. 1975; 44(2): 313–325. [PubMed: 48485]
- Simon-Sanchez J, Dopper EG, Cohn-Hokke PE, Hukema RK, Nicolaou N, Seelaar H, et al. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. *Brain : a journal of neurology*. 2012; 135(Pt 3):723–735. [PubMed: 22300876]
- Snowden JS, Pickering-Brown SM, Mackenzie IR, Richardson AM, Varma A, Neary D, et al. Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. *Brain : a journal of neurology*. 2006; 129(Pt 11):3091–3102. [PubMed: 17003069]
- Tzenova J, Kaplan BJ, Petryshen TL, Field LL. Confirmation of a dyslexia susceptibility locus on chromosome 1p34-p36 in a set of 100 Canadian families. *American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics*. 2004; 127B(1):117–124.
- Weintraub S, Fahey C, Johnson N, Mesulam MM, Gitelman DR, Weitner BB, et al. Vasectomy in men with primary progressive aphasia. *Cogn Behav Neurol*. 2006; 19(4):190–193. [PubMed: 17159614]
- Weintraub, S.; Mesulam, M-M. Four neuropsychological profiles in dementia. In: Boller, F.; Grafman, J., editors. *Handbook of Neuropsychology*. Amsterdam; Elsevier: 1993. p. 253-281.

Highlights

- Determinants of selective vulnerability in neurodegenerative diseases remain elusive.
- Identification of risk factors in PPA may help to understand what makes the language network vulnerable to disease.
- Genetic, developmental and acquired factors should be considered as potential susceptibility factors for PPA.

Figure 1.

Data from Rogalski 2008 showing that individual and family history of learning disability is significantly elevated in the PPA group compared with the other groups, $p < 0.001$.

Figure 2.

A) Data from Weintraub 2006 and B) unpublished data showing that the frequency of vasectomy was significantly higher in men with PPA than in comparison groups of healthy controls or individuals with the behavioral variant of frontotemporal dementia (bvFTD).